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Abstract: Thymomas are neoplasms arising from the epithelial
thymic cells, with a recurrence rate after complete resection ranging
from 5 to 50%, according to the initial stage of disease. The pleura
is the most frequent site of relapse, while distant metastases occur in
less than 5% of the cases. Data in the literature show that recurrences
can occur several years after the resection of a thymoma; unfortu-
nately, few reports have analyzed the treatment of recurrences of
thymoma. There is no standard treatment for the recurrent disease,
and most of the treatments proposed by the authors are based more
on their personal experience and individualized treatment than on an
evidence-based method. Moreover, most series concerning surgery
for recurrent thymomas suffer from a selection bias: patients with
limited disease and better performance status are usually selected for
surgery, with an anticipated survival advantage in the surgical
group. Surgery for recurrent thymoma is indicated if complete
resection is feasible, whereas in the case of predicted debulking
surgery, it may be considered as part of a multidisciplinary protocol.
In the literature, a few case reports of the surgical treatment of
metachronous distant metastases to liver or brain from thymoma
have been described, but they are really rare, and a decision about
their treatment is always on a single patient basis. We can conclude
that reoperation for thymoma recurrences is feasible and relatively
safe, and it should always be considered because the other treatment
modalities are not curative.
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If thymoma is rare, recurrences from resected thymomasare even rarer.1,2 Different treatments have been re-
ported, most as case reports.3,4 Selection bias is a major
issue, because there is no evidence-based method and,
overall, the literature is poor.5,6
The pattern of recurrence of resected thymomas in-
cludes local recurrence, pleural implants, and systemic me-
tastases. The incidence ranges from 5 to 50% and is related to
the initial stage of disease.
Stage of disease is the major prognostic factor7 and is
also the World Health Organization’s histologic classifica-
tion.8 B2 and B3 thymomas should be considered at higher
risk of relapse. If the primary resection was not radical, as can
happen for some invasive thymomas and stage IVA, the
definition of recurrence may not be appropriate. The invasion
of great vessels and the size of the thymoma have been
described as additional prognostic factors.9
In the literature, the largest series on the surgical
treatment of recurrent thymomas are small series obtained by
adding up all types of recurrences; common findings in these
series is a long mean interval to recurrence.5,6,10,11
Local recurrence can be considered as a failure of the
surgical treatment, and many consider adjuvant radiotherapy
as potentially able to prevent local recurrence. Unfortunately,
in stage II, the results are controversial,12 with most reports
showing no benefit or a detrimental effect.13 Even stage III
radiotherapy failed to give clear benefits in terms of disease-
free and overall survival.14
At the present time, the mostly accepted indications to
adjuvant radiotherapy are:
Y Resection performed macroscopically or microscopi-
cally not radical, particularly in case of thymomas,
peeled off the phrenic nerve or great vessels.
Y In case of any doubts about radicality of the resection,
type B2/3, because it is more aggressive.
Y In case of biopsies through mediastinotomy.
In our opinion, in some instances, when a thymoma is
resected by means of mini-invasive procedures (VATS and/or
robot), radicality can be compromised. These procedures
proved to be feasible in case of thymomas; however, some
major concerns still exist about the oncological propriety.
Above all, in case of thymomas greater than 2 cm and without
fat tissue surrounding the thymic capsule, the manipulation of
the tumor may cause seeding of tumor cells that are respon-
sible for local and pleural recurrences. We have already
experienced one case of local relapse (Fig. 1) and two cases
of pleural implants after the resection of early-stage thymo-
mas by VATS.
Usually local recurrences are approached through a
resternotomy or a hemi clamshell or clamshell approach,
according to the surgeon’s preference. These are usually
difficult operations because of the adhesions caused by the
previous operation and the adhesion/infiltrations with the
phrenic nerves and great vessels. The complete resection rate
is usually low, about 50 to 60%,5,6,10 but considering that
adjuvant radiotherapy has mostly already been given after the
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thymoma resection, surgery is the only local treatment avail-
able in a multimodality setting.
Pleural relapse is more frequent. It accounts for less
than 10% of resected thymomas,11 but they represent about
75% of the overall recurrences.10 It is not clear whether
they are related to the particular biology of the tumor or
whether they are consequences of seeding of the tumor,
possibly determined by disruption of the capsule during
the operation. For this reason, some surgeons recommend
to avoid opening the mediastinal pleura and avoid mini-
invasive procedures with a transpleural approach (thoracot-
omy, VATS, or robot assisted).15,16
Pleural recurrences are sometimes single and usually in
the vertebral douche, near the diaphragm; more frequently,
they are multiple, sometimes along the mediastinal pleura.
Often the diaphragm is involved; in such case, a partial
resection is necessary, and the deficit can be sutured with
nonabsorbable single stitches.
Sometimes pleural recurrences are extensive, with huge
pleural implants infiltrating the lung and the diaphragm; in
such cases, an extended pleuropneumonectomy, usually re-
served to malignant mesothelioma, and already proposed by
Wright17 for the treatment of advanced stage IVA thymoma
and pleural relapse, may be the only chance to attempt
radicality.
An attractive treatment of the pleural implants of thy-
moma is hyperthermic intrapleural chemotherapy. Refaely
et al.18 described 15 cases of thymic malignancies with
pleural spread, six of them were recurrent disease, treated by
resection and hyperthermic intrapleural chemotherapy. The
treatment was feasible and achieved an excellent local con-
trol. We also have experience with this technique and treated
our last seven cases of pleural recurrences by resection and
hyperthermic intrapleural perfusion with two drugs (cisplatin
and doxorubicin) for 1 hour at 41 to 42°C.
Recently, we reviewed and published our institutional
experience on the surgical treatment of pleural recurrences of
thymoma.11 In an update of our experience of the surgical
resection of all the recurrences of thymoma, we identified 34
patients. There were two local relapses, two liver metastases,
two peritoneal metastases, and 28 pleural implants.
FIGURE 2. CT showing pleural (A) and transdiaphragmatic
retroperitoneal (B) metastasis.
FIGURE 1. Chest CT (A) of a 36-year-old woman who was
operated on in another institution for a stage II B3 thymoma
by left VATS and who experienced 2 years later a recurrence
in the chest wall near the thymoma. She underwent resec-
tion of the recurrence en bloc with 2 ribs (B).
Journal of Thoracic Oncology • Volume 5, Number 10, Supplement 4, October 2010 Surgical Treatment of Recurrent Thymomas
Copyright © 2010 by the International Association for the Study of Lung Cancer S349
Most of the patients (n  20) had an initial stage III
thymoma, and the median interval between the resection of
the thymoma and the recurrence was 55 months. A thymus-
related syndrome was present in 21 cases, mostly myasthenia
gravis. Four patients underwent repeat resections of pleural
implants. The overall perioperative mortality was nil and
morbidity was mild.
Focusing on the cases of pleural recurrence, the major-
ity of patients had multiple implants and 10 cases showed a
diaphragmatic involvement. With an update of the recently
published series,11 overall 5- and 10-year survivals from the
pleural recurrence resection were 44.7 and 27.1%, respec-
tively. Comparing the survival of the single metastasis group
with the multiple metastases, we found that single metastasis
had a statistically significant better survival than multiple
metastases. Moreover, patients with diaphragmatic involve-
ment showed a significantly worse prognosis.
Transdiaphragmatic retroperitoneal metastasis can oc-
cur at diagnosis or after a resection of pleural relapse.19 We
also identified two such cases (Fig. 2) and decided to ap-
proach simultaneously the resection of the pleural implants
by a thoracotomy and the peritoneal implants by a lum-
botomy or a laparotomy. It can be expected, similarly to what
occurs with malignant pleural mesothelioma after an ex-
tended pleuropneumonectomy, that after the resection of
pleural implants involving the diaphragm, peritoneal implants
will be experienced. With a longer follow-up, the incidence
of peritoneal implants will increase, and there will be a
surgical challenge.
Sometimes, we face advanced metastatic thymoma, and
surgeons, oncologists, or radiotherapists do not have good
arms to treat these patients. Particularly, surgery does not
seem to play any role when the disease is systemic, but some
dramatically unconventional cases require a multidisciplinary
evaluation and the exploration of new treatments.
As an example, 2 years ago, we treated a 32-year-old
man who had undergone a multimodality treatment (neoad-
juvant chemotherapy, surgery, and adjuvant radiotherapy) in
2002 for an invasive stage III thymoma. In May 2004, he had
multiple pleural implants treated by six courses of a second-
line chemotherapy and then somatostatin LAR and pred-
nisone. In 2006, a pleurectomy plus partial diaphragmatic
FIGURE 3. CT showing a pulmonary metastasis on the right and thoracoplasty-like effect on the left (A). A huge peritoneal
metastasis surrounding the spleen, dislocating the stomach and the kidney (B). The resection of the peritoneal mass en bloc
with the spleen (C).
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resection and hyperthermic chemotherapy with doxorubicin
were performed at another institution. Then, the patient un-
derwent radiotherapy on the chest wall and single drug
chemotherapy. In 2007, there was pleural and peritoneal
progression.
In April 2008, he was referred to our center with a chest
computed tomography showing a pulmonary metastasis on
the right and thoracoplasty-like effect on the left, a huge
peritoneal metastasis surrounding the spleen, dislocating the
stomach and the kidney (Figure 3). On the right lobe of the
liver, there was a peritoneal mass that was defined as a liver
metastasis at preoperative staging. A suspicion of lumbar
vertebral metastasis was also present.
We decided to enroll the patient in a phase I study of
radioimmuno therapy, debulking of the peritoneal mass that
caused major symptoms for the patient at that time (Figure 3).
We removed the mass en bloc with the spleen and also a lot
of peritoneal implants. It was not a liver metastasis but a
peritoneal implant compressing the liver. On the surgical
specimen, we studied the extradomain  of fibronectin, an
oncofetal antigen expressed at various levels in the stroma of
a large variety of neoplastic tissues, and we found it to be
highly expressed. In such cases, surgery is mainly to palliate
symptoms and to provide tissue for a biologic characteriza-
tion necessary for target therapies.
The treatment of distant metastasis from thymoma,
synchronous or metachronous, should be discussed in a
multimodality setting and on a single patient basis. In the
literature, a few case reports of resection of single distant
metastasis have been described with good results.20,21 We
also had two patients who underwent resection of metachro-
nous single-liver metastasis, resulting in long-term survival
(63 and 89 months, respectively, from the liver resection).
Obviously, surgery should not be proposed to all patients
with distant metastases of thymoma, but whenever metastases
are single or easily resectable or with a long disease-free
interval, surgical resection should be considered.
So we can conclude that reoperation and also re-
reoperation of thymoma recurrences are feasible and safe. It
allows a good overall survival and paraneoplastic syndrome
control.
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